secwatch.observer — SEC 8-K summary
======================================

Issuer:     Disc Medicine, Inc. (IRON)
CIK:        0001816736
Form:       8-K
Filed at:   2022-04-05T23:59:59+00:00
Accession:  0001193125-22-095633
Event type: leadership
Sentiment:  negative
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Gemini Therapeutics CMO Samuel Barone to depart April 15, 2022; advisory role continues
--------------------------------------------------------------------------------

- Dr. Samuel Barone will leave as Chief Medical Officer effective April 15, 2022.
- He receives 9 months base salary severance, pro-rata 2022 target bonus, and 9 months COBRA.
- Barone will stay on as advisor, continuing to vest in existing equity during the advisory period.
- Retention Agreement terms from Oct 4, 2021 govern severance; general release required.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816736/000119312522095633/0001193125-22-095633-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816736/000119312522095633/d345871d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-095633

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer